CADD522

CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer[1][2].

Product Specifications

CAS Number

[199735-88-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cadd522.html

Concentration

10mM

Purity

98.23

Solubility

DMSO : ≥ 100 mg/mL

Smiles

ClC1=C(Cl)C=CC(NC(C2C(C3)C=CC3C2C(O)=O)=O)=C1

Molecular Formula

C15H13Cl2NO3

Molecular Weight

326.17

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim MS, et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8 (41) :70916-70940. |[2]Kim MS, et al. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 2020 Oct 27;11 (43) :3863-3885.